2012-09-28 12:04:19 - With an additional 1.63 Million new people expected to be diagnosed with cancer in 2012, the total number of cancer patients in the US is likely to reach an annoying figure of 16.5 Million by the end of the year, says RNCOS.
A new research report from RNCOS reveals that despite burgeoning efforts by the US health authorities, cancer incidence rates in the US are on rise. The country is likely to witness around 577,190 deaths from cancer in 2012. If the current trend persists, this number is likely to reach around 592,300 by 2016, taking the total prevalence to a staggering figure of 21.2 Million. Further, California leads in terms of total number of new cases followed by Florida, Texas, and New York. California, in 2012, is expected to witness around 165,810 new cases of cancer mainly in female breast, prostate, lung & bronchus and colon & rectum.
These figures pose serious challenges for the US Government and offers immense opportunities for
the players that offer personalized cancer whole genome sequencing (WGS). Personalized diagnosis of patient’s genome facilitates personalized cancer treatment and saves on unnecessary drug-related complications and costs, making it an attractive option for both the patient and health care provider. This sector thus stands a responsibility of catering to a huge population of cancer patients that present a soaring potential market.
The report entitled “US Personalized Cancer Genome Sequencing Market” provides an extensive research and in-depth analysis of the current status and expected position of the US market for personalized WGS intended for diagnosing cancer. It evaluates the current status and future potential of the market and focuses on the strengths and weaknesses of the market players.
Moreover, the report projects the future size of the market till 2016. In this context, it illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of the regulatory environment has also been provided.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM453.htm
Some of our Related Reports are:
- Brazil Healthcare - New Opportunities for Growth (http://www.rncos.com/Report/IM451.htm)
- US Non-Invasive Prenatal Diagnostics - Market Insight (http://www.rncos.com/Report/IM450.htm)
- US Cardiac Device Market Analysis (http://www.rncos.com/Report/IM441.htm)
- US Clinical Laboratory Testing Market Assessment (http://www.rncos.com/Report/IM442.htm)
- Global Genetic Testing Market Forecast to 2015 (http://www.rncos.com/Report/IM445.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.